Journal article

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca

NL Galvão-Coelho, AC de Menezes Galvão, RN de Almeida, F Palhano-Fontes, I Campos Braga, B Lobão Soares, JP Maia-de-Oliveira, D Perkins, J Sarris, DB de Araujo

Journal of Psychopharmacology | SAGE PUBLICATIONS LTD | Published : 2020

Abstract

Background: Ayahuasca is a traditional Amazon brew and its potential antidepressant properties have recently been explored in scientific settings. We conducted a double-blind placebo-controlled trial of ayahuasca with treatment-resistant depression patients (n = 28) and healthy controls (n = 45). Aims: We are evaluating the blood inflammatory biomarkers: C-reactive protein and interleukin 6, as a potential consequence of ayahuasca intake and their correlation with serum cortisol and brain-derived neurotrophic factor levels. Blood samples were collected at pre-treatment and 48 hours after substance ingestion to assess the concentration of inflammatory biomarkers, together with administration ..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Brazilian National Council for Scientific and Technological Development (CNPq, grants 466760/2014 and 479466/2013), CAPES Foundation within the Brazilian Ministry of Education (grants 1677/2012 and 1577/2013) and by National Science and Technology Institute for Translational Medicine (INCT-TM Fapesp 2014/50891-1; CNPq 465458/2014-9). NLGC is supported by CAPES Foundation from Brazilian Ministry of Education (Research Fellowship 88887.466701/2019-00). JS is supported by an NHMRC Clinical (Fellowship APP1125000).